Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ME2 | P23368 | 1/20 | 0.40 |
| ▸ | ME1 | P48163 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8654425 | 0.78 | DYRK1A (0.50) | CLK4DYRK1AMAPTKDM4ETP53 | |
| SCHEMBL2090042 | 0.73 | CA12 (0.46) | CA12CA1CA2CA7CA9 | |
| SCHEMBL197522 | 0.69 | CA1 (0.79) | CA12CA1CA2CA7CA9 | |
| SCHEMBL6733562 | 0.69 | CA1 (0.79) | CA12CA1CA2CA7CA9 | |
| SCHEMBL9151672 | 0.69 | CA1 (0.79) | CA12CA1CA2CA7CA9 | |
| SCHEMBL19100022 | 0.68 | CA12 (0.44) | CA12CA1CA2CA7CA9 | |
| SCHEMBL28890215 | 0.67 | CA1 (0.73) | CA12CA1CA2CA7CA9 | |
| Iodide SCHEMBL28861996 | 0.67 | CA1 (0.73) | CA12CA1CA2CA7CA9 | |
| SCHEMBL4094356 | 0.67 | KDM4E (0.71) | CA12CA1CA2CA7CA9 | |
| SCHEMBL29733664 | 0.67 | KDM4E (0.71) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240156792-A1 | COMBINATION THERAPY USING AZABICYCLO COMPOUND FOR CANCER | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-05-16 | — | — | US | disclosed |
| US-11918562-B2 | Combination therapy using azabicyclo compound for cancer | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-03-05 | — | — | US | disclosed |
| US-20220016090-A1 | COMBINATION THERAPY USING AZABICYCLO COMPOUND FOR CANCER | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2022-01-20 | — | — | US | disclosed |
| US-11166943-B2 | Combination therapy using azabicyclo compound for cancer | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-11-09 | — | — | US | disclosed |
| US-10849886-B2 | Combination therapy using azabicyclo compound for cancer | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-12-01 | — | — | US | disclosed |
| US-20200281904-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR DISEASES INVOLVING IDO EXPRESSION | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-09-10 | — | — | US | disclosed |
| US-20200276171-A1 | COMBINATION THERAPY USING AZABICYCLO COMPOUND FOR CANCER | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-09-03 | — | — | US | disclosed |
| EP-3682900-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR DISEASES INVOLVING IDO EXPRESSION | Taiho Pharmaceutical Co., Ltd. (JP) | 2020-07-22 | — | — | EP | disclosed |
| EP-3646869-A1 | CHEMOTHERAPY FOR CANCER USING AZABICYCLO COMPOUND | Taiho Pharmaceutical Co., Ltd. (JP) | 2020-05-06 | — | — | EP | disclosed |
| CN-111107876-A | Prophylactic and/or therapeutic agent for diseases in which IDO expression is involved | 大鹏药品工业株式会社 | 2020-05-05 | — | — | CN | disclosed |
| US-20160228417-A1 | COMBINATION THERAPY USING AZABICYCLO COMPOUND FOR CANCER | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | disclosed |
| EP-3053578-A1 | COMBINATION CANCER THERAPY USING AZABICYCLO COMPOUND | Taiho Pharmaceutical Co., Ltd. (JP) | 2016-08-10 | — | — | EP | disclosed |
| US-9273045-B2 | Azabicyclo compound and salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2016-03-01 | — | — | US | disclosed |
| EP-2452940-B1 | AZABICYCLO COMPOUND AND SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2014-12-17 | — | — | EP | disclosed |
| US-20140303162-A1 | AZABICYCLO COMPOUND AND SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2014-10-09 | — | — | US | disclosed |
| US-8779142-B2 | Azabicyclo compound and salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2014-07-15 | — | — | US | disclosed |
| EP-2452940-A1 | AZABICYCLO COMPOUND AND SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2012-05-16 | — | — | EP | disclosed |
| US-20120108589-A1 | AZABICYCLO COMPOUND AND SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2012-05-03 | — | — | US | disclosed |
| CN-1066150-C | Bridged indoles as matrix metalloprotease inhibitors | SYNTEX INC (US) | 2001-05-23 | — | — | CN | disclosed |
| CN-1180358-A | Bridged indoles as matrix metalloprotease inhibitors | SYNTEX INC (US) | 1998-04-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303162-A1 | AZABICYCLO COMPOUND AND SALT THEREOF | HSP90AB1, HSP90AB2P, HSP90AA1 | CA12 2723/4885CA1 1691/4885CA2 686/4885 |
| US-20240156792-A1 | COMBINATION THERAPY USING AZABICYCLO COMPOUND FOR CANCER | HSP90AB1, HSP90AA1, HSP90AB2P | CA12 3176/4885CA1 2696/4885CA2 2262/4885 |
| US-20160228417-A1 | COMBINATION THERAPY USING AZABICYCLO COMPOUND FOR CANCER | HSP90AB1, HSP90AA1, HSP90AB2P | CA12 3176/4885CA1 2696/4885CA2 2262/4885 |
| US-20120108589-A1 | AZABICYCLO COMPOUND AND SALT THEREOF | HSP90AB1, HSP90AB2P, HSP90AA1 | CA12 2723/4885CA1 1691/4885CA2 686/4885 |
| US-11918562-B2 | Combination therapy using azabicyclo compound for cancer | HSP90AB1, HSP90AA1, HSP90AB2P | CA12 3176/4885CA1 2696/4885CA2 2262/4885 |
| US-10849886-B2 | Combination therapy using azabicyclo compound for cancer | HSP90AB1, HSP90AA1, HSP90AB2P | CA12 3176/4885CA1 2696/4885CA2 2262/4885 |
| US-20200276171-A1 | COMBINATION THERAPY USING AZABICYCLO COMPOUND FOR CANCER | HSP90AB1, HSP90AA1, HSP90AB2P | CA12 3176/4885CA1 2696/4885CA2 2262/4885 |
| US-20220016090-A1 | COMBINATION THERAPY USING AZABICYCLO COMPOUND FOR CANCER | HSP90AB1, HSP90AA1, HSP90AB2P | CA12 3176/4885CA1 2696/4885CA2 2262/4885 |
| US-11166943-B2 | Combination therapy using azabicyclo compound for cancer | HSP90AB1, HSP90AA1, HSP90AB2P | CA12 3176/4885CA1 2696/4885CA2 2262/4885 |
| US-20200281904-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR DISEASES INVOLVING IDO EXPRESSION | IDO1, IDO2, HSP90AB1 | CA12 3490/4885CA1 3484/4885CA2 4104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.